NLSPW NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM)
- 0.0350
- 0.00000.00%
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) News
20-F: Registration statement / Annual report / Transition report
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) today announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc., a privately held U.S. company ("Aexon Labs"), under which NLS may acquire global development and commercialization rights to Aexon Labs' Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin-1 and orexin-2 receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders such as Parkinson's and Alzheimer's disease.
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive Into Narcolepsy and Idiopathic Hypersomnia
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery a
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3,NLS to Webcast its Event Friday, October 20 at 11:00am ETZURICH, SWITZERLAND / ACCESSWIR
NLS Pharmaceutics to Proceed With Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE. In addition, the Company is pleased to announce that the Phase 3 clinical trial protocol to evaluate the safety and efficacy of Mazindol ER in patients with narcolepsy type 1 received approval from the independent Institutional Review Board ("IRB").
NLS Pharmaceutics Releases the Results From Its Annual General Meeting
ZURICH, SWITZERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ETZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ETZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss cli
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
NLS Pharmaceutics Announces Company Update Webcast
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
ZURICH, SWITZERLAND / ACCESSWIRE / April 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
ZURICH, SWITZERLAND / ACCESSWIRE / January 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco
NLS Pharmaceutics Announces Compliance With Nasdaq Bid Price Requirement
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an
NLS Pharmaceutics CEO Issues Letter To Shareholders
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for pati
Analysis
Price Target
No Data
